Chemotherapy plus Vandetanib or Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of Four Randomised Controlled Trials

Clinical Oncology

Volumn 25, Issue 1, 2013, Pages

  Xiao, Yong Ying ^a   Zhan, Ping ^b   Yuan, Dong Mei ^a   Liu, Hong Bing ^a   Lv, Tang Feng ^a   Shi, Yi ^a   Song, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING CHEST HOSPITAL   (China)

Author keywords

Meta analysis; Non small cell lung cancer; Overall response rate; Overall survival; Progression free survival; Randomised controlled trials; Vandetanib

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL; PEMETREXED; VANDETANIB;

ADVANCED CANCER; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; COCHRANE LIBRARY; COUGHING; DIARRHEA; DRUG EFFICACY; FATIGUE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTEMIC THERAPY; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PIPERIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84871449816     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.09.005     Document Type: Article

References (31)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Alberg A., Ford J., Samet J. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007, 132:29S-55S.
3. Stinchcombe T.E., Socinski M.A. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:233-241.
4. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
5. Fossella F.V., De Vore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
6. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
7. Molina J.R., Yang P., Cassivi S.D., et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
8. Sandler A., Gray R., Perry M.C., et al. Paclitaxel carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006, 355:2542-2550.
9. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
10. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
11. Pennell N.A., Mekhai T. Investigational agents in the management of non-small cell lung cancer. Curr Oncol Rep 2009, 11:275-284.
12. Ciardiello F., Troiani T., Bianco R., et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multitarget anticancer therapy. Ann Oncol 2006, 17. vii109-vii114.
13. Naumov G.N., Nilsson M.B., Cascone T., et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009, 15:3484-3494.
14. Pennell N.A., Lynch T.J. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009, 14:399-411.
15. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
16. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62:7284-7290.
17. Tamura T., Minami H., Yamada Y., et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006, 1:1002-1009.
18. Herbst R.S., Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11:619-626.
19. de Boer R.H., Arrieta O., Yang C.H., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29:1067-1074.
20. Heymach J.V., Paz-Ares L., De Braud F., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:5407-5415.
21. Heymach J.V., Johnson B.E., Prager D., et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007, 25:4270-4277.
22. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
23. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997, 315:629-634.
24. Rodrigo D., Pablo M., Enriqueta F. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011, 2:165-177.
25. Wang F., Wang L.D., Li B., Sheng Z.X. Gefitinib compared with systemic chemotherapy as first-line treatment for chemo-therapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials. Clin Oncol (R Coll Radiol) 2012, 24(6):396-401.
26. Sumanta K.P., Robert A.F., Karen R. Targeted therapies for non-small cell lung cancer:an evolving landscape. Mol Cancer Ther 2010, 9:1931-1944.
27. Ulahannan S.V., Brahmer J.R. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 2011, 29(4):325-337.
28. Lee J.S., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012, 30(10):1114-1121.
29. Herbst R.S. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006, 8(Suppl. 1):S23-S30.
30. Ricciardi S., Tomao S., de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009, 10:28-35.
31. Begg C.B., Berlin J.A. Publication bias: a problem in interpreting medical data. J R Stat Soc A 1988, 151:419-463.